AstraZeneca

News

GSK claims a first with Jemperli in endometrial cancer

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.

News

ESMO: J&J’s Tagrisso challenge, and other highlights

With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.

News

AZ seeks FDA okay for first self-administered flu vaccine

The FDA has started a review of an extension to the labelling for AstraZeneca’s influenza vaccine FluMist Quadrivalent which would allow it to be administered by patients

News

AZ’s Tagrisso plus chemo get fast FDA review for lung cancer

AstraZeneca will hear back from the FDA in the first quarter of next year about its recent filing of Tagrisso in combination with chemotherapy as a first-line treatment fo

News

AZ pays $425m to settle claims heartburn drugs caused harm

AstraZeneca confirmed this morning it has agreed to pay $425 million to settle lawsuits brought in the US that claim its heartburn therapies Nexium and Prilosec caused kid

News

J&J doublet beats Tagrisso in first-line lung cancer

AstraZeneca’s Tagrisso could face some serious competition as a first-line targeted therapy for advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), in

GSK claims a first with Jemperli in endometrial cancer

ESMO: J&J’s Tagrisso challenge, and other highlights

AZ seeks FDA okay for first self-administered flu vaccine

AZ’s Tagrisso plus chemo get fast FDA review for lung cancer

AZ pays $425m to settle claims heartburn drugs caused harm

J&J doublet beats Tagrisso in first-line lung cancer

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

AstraZeneca

Editor's Picks